Intestinal Microbiological Analysis, Obesity Management...Personalized healthcare for pets is evolving
Dec 20, 2024
"Personnel population"10 million". The need for health and longevity of dogs and cats living together is stronger than ever.
According to the KB Management Research Institute's '2023 Korea Pet Report', 55% of households with pets cited issues related to 'health care' as their concerns. Interest in management methods such as health checkups (68.6%) and care methods after disease diagnosis (55.7%) were found to be the highest.
Accordingly, the application of healthcare technology for customized health care as well as medicines and nutritional supplements for companion animals is rapidly spreading.
Macrogen's pet genetic testing brand, 'myPETGENE', recently launched the 'Puppy Intestinal Microbiological Analysis' service. It provides analysis of a total of eight items, including basic bowel disease and arthritis, dermatitis, behavioral disorders, obesity, diabetes, cardiovascular disease, and kidney failure.
By analyzing the distribution and diversity of microorganisms living in the intestines of companion animals, the health status of companion animals can be comprehensively checked. Macrogen provides companion animal intestinal microbiological analysis using the next-generation sequencing (NGS) platform and the largest dielectric data in Korea built on its own. Through this, pets can preemptively manage and prevent their pets through customized health care guides and various contents provided by Macrogen.
In the future, Macrogen plans to expand and develop services starting with the analysis of intestinal microorganisms in dogs and the analysis of intestinal microorganisms in cats. In addition, it plans to predict genetic diseases of pets early through specialized analysis services such as oral and skin microbiological tests as well as intestinal microbial imbalance analysis, and to help prevent diseases and manage health by providing customized eating and exercise solutions.
He is also studying how to manage his dog's weight. Weight management is essential because obesity in pets causes various diseases such as inflammation, diabetes, high blood pressure, and heart disease.
Recently, Cell Biotech published the results of its research on dogs 'Pet Lactobacillus Weight Loss' in the SCI-class international academic journal 'Scientific Reports (IF: 3.8)'. ▲weight ▲blood condition ▲body fidelity index (BCS) ▲ intestinal microbiome changes in 41 dogs with overweight and obese conditions for 12 weeks, and 'duopet lactobacillus by DUOLAC' were found to be very effective in reducing dog weight.
Pet-like bacteria using "100% Human Grade" raw materials have 20 billion lactobacilli and contain 200 mg of glucosamine as a subsidiary material, which can comprehensively manage the joint health of pets. In particular, considering the body temperature (38-39 degrees) of pets higher than humans, the world patent 'dual coating' technology has been applied to verify the survival of lactobacilli in an environment of 40 degrees.
Pharmaceutical companies are no exception. Daewoong Pharmaceutical has entered the pet healthcare business, including pharmaceuticals, through Daewoong Pet and Dong-A Pharmaceutical has entered the pet healthcare business through 「Betple」, and Dong-A Pharmaceutical, Yuyu Pharmaceutical, Ildong Pharmaceutical, and Chong Kun Dang Bio are in the midst of developing and selling health functional foods and medicines for companion animals.
An industry official diagnosed "With the increase of the population, the pet health-related business has emerged as the future food of the healthcare sector."
According to a report published by the Korea Rural Economic Research Institute, the size of the global pet-related market is expected to grow to $378.1 billion (532 trillion won) in 2022, with an average annual growth of 7.5% to $780.4 billion (1098 trillion won) in 2032.
Reporter Kim So-hyung compact@sportschosun.com
According to the KB Management Research Institute's '2023 Korea Pet Report', 55% of households with pets cited issues related to 'health care' as their concerns. Interest in management methods such as health checkups (68.6%) and care methods after disease diagnosis (55.7%) were found to be the highest.
Accordingly, the application of healthcare technology for customized health care as well as medicines and nutritional supplements for companion animals is rapidly spreading.
|
By analyzing the distribution and diversity of microorganisms living in the intestines of companion animals, the health status of companion animals can be comprehensively checked. Macrogen provides companion animal intestinal microbiological analysis using the next-generation sequencing (NGS) platform and the largest dielectric data in Korea built on its own. Through this, pets can preemptively manage and prevent their pets through customized health care guides and various contents provided by Macrogen.
In the future, Macrogen plans to expand and develop services starting with the analysis of intestinal microorganisms in dogs and the analysis of intestinal microorganisms in cats. In addition, it plans to predict genetic diseases of pets early through specialized analysis services such as oral and skin microbiological tests as well as intestinal microbial imbalance analysis, and to help prevent diseases and manage health by providing customized eating and exercise solutions.
He is also studying how to manage his dog's weight. Weight management is essential because obesity in pets causes various diseases such as inflammation, diabetes, high blood pressure, and heart disease.
Recently, Cell Biotech published the results of its research on dogs 'Pet Lactobacillus Weight Loss' in the SCI-class international academic journal 'Scientific Reports (IF: 3.8)'. ▲weight ▲blood condition ▲body fidelity index (BCS) ▲ intestinal microbiome changes in 41 dogs with overweight and obese conditions for 12 weeks, and 'duopet lactobacillus by DUOLAC' were found to be very effective in reducing dog weight.
Pet-like bacteria using "100% Human Grade" raw materials have 20 billion lactobacilli and contain 200 mg of glucosamine as a subsidiary material, which can comprehensively manage the joint health of pets. In particular, considering the body temperature (38-39 degrees) of pets higher than humans, the world patent 'dual coating' technology has been applied to verify the survival of lactobacilli in an environment of 40 degrees.
Pharmaceutical companies are no exception. Daewoong Pharmaceutical has entered the pet healthcare business, including pharmaceuticals, through Daewoong Pet and Dong-A Pharmaceutical has entered the pet healthcare business through 「Betple」, and Dong-A Pharmaceutical, Yuyu Pharmaceutical, Ildong Pharmaceutical, and Chong Kun Dang Bio are in the midst of developing and selling health functional foods and medicines for companion animals.
An industry official diagnosed "With the increase of the population, the pet health-related business has emerged as the future food of the healthcare sector."
According to a report published by the Korea Rural Economic Research Institute, the size of the global pet-related market is expected to grow to $378.1 billion (532 trillion won) in 2022, with an average annual growth of 7.5% to $780.4 billion (1098 trillion won) in 2032.
Reporter Kim So-hyung compact@sportschosun.com
compact@sportschosun.com
